Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS

v3.26.3
REVENUES FROM CONTRACTS WITH CUSTOMERS
 9 Months Ended
Sep. 30, 2026
REVENUES FROM CONTRACTS WITH CUSTOMERS  
REVENUES FROM CONTRACTS WITH CUSTOMERS

NOTE 15. REVENUES FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Net Revenues

The Company has the following actively marketed products: Emrosi®, Qbrexza®, Amzeeq®, Zilxi®, Accutane®, Eurax®, Exelderm®, Targadox®, and Luxamend®. All of the Company’s product revenues are recorded in the U.S.

Revenues by product are summarized as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended

​

Nine-Month Periods Ended

​

​

September 30, 

​

September 30, 

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi®

​

$

9,002

​

$

4,883

​

$

23,329

​

$

9,748

Qbrexza®

​

​

5,590

​

​

7,361

​

​

15,732

​

​

19,470

Accutane®

​

 

3,023

​

 

2,769

​

 

9,694

​

 

9,818

Foam franchise products (Amzeeq® & Zilxi®)

​

​

942

​

​

1,311

​

​

2,933

​

​

3,973

Other / legacy

​

​

368

​

​

701

​

​

997

​

​

2,164

Total product revenues

​

$

18,925

​

$

17,025

​

$

52,685

​

$

45,173

​

The Company recognized other revenue as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended 

​

Nine-Month Periods Ended

​

​

September 30, 

​

September 30, 

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Cutia supply agreement

​

$

—

​

$

606

​

$

635

​

$

606

Royalties on sales of Amzeeq by Cutia

​

​

42

​

​

—

​

​

118

​

​

—

Total other revenue

​

$

42

​

$

606

​

$

753

​

$

606

​

Other revenue for the three and nine-month period ended September 30, 2026 reflects the supply of Amzeeq to Cutia as well as sales-based royalties earned on the net sales of Amzeeq by Cutia.

Significant Customers

For the three and nine-month periods ended September 30, 2026 and 2025 there were no customers that accounted for more than 10% of the Company’s total gross product revenue.

At September 30, 2026 and December 31, 2025, none of the Company’s customers accounted for more than 10% of its total accounts receivable balance.